Introduction to specifications and packaging information of Pegcetacoplan-Empaveli

Pegcetacoplan is a new type of complement inhibitor. Its core function is to regulate the activity of complement C3 in the immune system, thereby preventing blood cell destruction or kidney damage caused by abnormal complement activation. Pegtak is widely used to treat rare blood and kidney diseases, especially paroxysmal nocturnal hemoglobinuria (PNH) and some complement-related nephropathies. The drug is used clinically as a subcutaneous injection and is designed to provide long-term and stable disease control.

In terms of specifications and packaging, Pegtak is usually sold in 1080mg/20ml (54mg/ml) format. Each bottle contains 20ml of solution, which is convenient for patients to self-inject in medical institutions or at home. This specification design not only meets the treatment needs of adult patients, but is also easy to use for adolescent patients aged 12 and above. In terms of indications, PegTak is approved for use in adult patients with PNH to help reduce hemolysis and the need for blood transfusions while improving hemoglobin levels and quality of life. In addition, PegTac can also be used in patients 12 years of age and older with C3 glomerulopathy (C3G) and patients with primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria and delay deterioration of renal function.

When administered by subcutaneous injection, the drug can directly inhibit the abnormally activatedC3 pathway in the blood and kidneys, thereby reducing complement-mediated red blood cell destruction and glomerular damage. PegTac has shown good efficacy and controllable safety in clinical trials, making it an important treatment option for patients with PNH and C3G/IC-MPGN. The concentration and volume designed in specifications can ensure that patients receive sufficient therapeutic doses in one injection, while reducing the number of injections and improving patient compliance.

In addition, Pegtuck's packaging takes into account storage and transportation conditions. Medications need to be kept refrigerated and returned to room temperature before use to ensure the stability of the efficacy. Each vial is usually packaged with an injection needle or connection device to facilitate self-injection at home and can be administered by a nurse in a health care facility.

Reference materials:https://go.drugbank.com/drugs/DB16694